Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.69 |
| ▸ | CA2 | P00918 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 5/20 | 0.69 |
| ▸ | CA7 | P43166 | 5/20 | 0.69 |
| ▸ | CA9 | Q16790 | 5/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.69 |
| ▸ | XDH | P47989 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15099889 | 0.82 | CA1 (0.77) | CA1CA2CA12CA7CA9 | |
| Methyl Protocatechuate SCHEMBL38624 | 0.82 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Methyl Protocatechuate SCHEMBL29360855 | 0.82 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7927352 | 0.81 | TDP1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7933008 | 0.79 | MAPT (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11872904 | 0.79 | ALDH1A1 (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL29501115 | 0.78 | CA12 (0.71) | CA1CA2CA12CA7CA9 | |
| SCHEMBL162631 | 0.78 | CA12 (0.71) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30809635 | 0.78 | CA1 (0.71) | CA1CA2CA12CA7CA9 | |
| SCHEMBL197972 | 0.78 | CA1 (0.71) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1091745-B1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDREN S HOSPITAL LOS ANGELE (US) | 2008-10-01 | — | — | EP | claimed |
| EP-2669267-B1 | Compositions and methods for treating hyperproliferative disorders | TEXAS TECH UNIV (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-1594544-B1 | ORAL COMPOSITIONS OF FENRETINIDE HAVING INCREASED BIOAVAILABILITY AND METHODS OF USING THE SAME | LOS ANGELES CHILDRENS HOSPITAL (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9050294-B2 | Treatment of neural diseases or conditions | ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-06-09 | — | — | US | disclosed |
| EP-2244702-B1 | TREATMENT OF NEURAL DISEASES OR CONDITIONS | UNIV MCGILL (CA) | 2014-09-17 | — | — | EP | disclosed |
| US-20140113973-A1 | TREATMENT OF NEURAL DISEASES OR CONDITIONS | ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-04-24 | — | — | US | disclosed |
| US-8642658-B2 | Treatment of neural diseases or conditions | ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-02-04 | — | — | US | disclosed |
| EP-2669267-A1 | Compositions and methods for treating hyperproliferative disorders | TEXAS TECH UNIVERSITY (US) | 2013-12-04 | — | — | EP | disclosed |
| US-20130217691-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | TEXAS TECH UNIVERSITY SYSTEM (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2501672-A2 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | TEXAS TECH UNIVERSITY (US) | 2012-09-26 | — | — | EP | disclosed |
| WO-2002058689-A1 | PHARMACEUTICAL COMPOSITIONS OF FENRETINIDE HAVING INCREASED BIOAVAILABILITY AND METHODS OF USING THE SAME | CHILDRENS HOSPITAL LOS ANGELES (US) | 2002-08-01 | — | — | WO | disclosed |
| US-6368831-B1 | ANTIPROLIFERATION AGENTS | CHILDRENS HOSPITAL LOS ANGELES | 2002-04-09 | — | — | US | disclosed |
| US-6352844-B1 | CERAMIDE GENERATING RETINOIDS AND INHIBITORS OF TUMORS | CHILDRENS HOSPITAL LOS ANGELES | 2002-03-05 | — | — | US | disclosed |
| WO-2001047513-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDRENS HOSPITAL LOS ANGELES RESEARCH INSTITUTE (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1091745-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDREN'S HOSPITAL OF LOS ANGELES (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001007914-A1 | FENRETINIDE INCREASES ANTIBODY CELLULAR TOXICITY | CHILDRENS HOSPITAL LOS ANGELES RESEARCH INSTITUTE (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000000207-A9 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | LOS ANGELES CHILDRENS HOSPITAL (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000000207-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDREN'S HOSPITAL OF LOS ANGELES (US) | 2000-01-06 | — | — | WO | disclosed |
| US-4190594-A | ABSORBERS OF ULTRAVIOLET RADIATION | JOHNSON & JOHNSON (US) | 1980-02-26 | — | — | US | disclosed |
| US-4108880-A | ULTRAVIOLET ABSORBERS | JOHNSON & JOHNSON (US) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113973-A1 | TREATMENT OF NEURAL DISEASES OR CONDITIONS | RARB, RARA, RARG | CA1 734/4885CA2 2880/4885CA12 1109/4885 |
| US-20130217691-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | SGMS1, S1PR1, SPHK1 | CA1 2999/4885CA2 2422/4885CA12 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.